In a note to clients, Jefferies writes, "We believe that commercial payers will see the value proposition that the addition of Tomosynthesis brings to the table. HOLX will be presenting to a private payer panel sometime in April to educate them on the sensitivity and specificity data from the reader studies presented at the FDA panel as well as other single center studies. Importantly, the cost savings associated with a reduced recall rate and unnecessary biopsy rate provide cost efficiency on top of the clinical efficacy generated in the reader studies."